Article
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Blood - 30 Jan 2014
Mulligan George, Lichter David I, Di Bacco Alessandra, Blakemore Stephen J, Berger Allison, Koenig Erik, Bernard Hugues, Trepicchio William, Li Bin, Neuwirth Rachel, Chattopadhyay Nibedita, Bolen Joseph B, Dorner Andrew J, van de Velde Helgi, Ricci Deborah, Jagannath Sundar, Berenson James R, Richardson Paul G, Stadtmauer Edward A, Orlowski Robert Z, Lonial Sagar, Anderson Kenneth C, Sonneveld Pieter, San Miguel Jesús F, Esseltine Dixie-Lee, Schu Matthew
Abstract excerpt
Various translocations and mutations have been identified in myeloma, and certain aberrations, such as t(4;14) and del17, are linked with disease prognosis. To investigate mutational prevalence in myeloma and associations between mutations and patient outcomes, we tested a panel of 41 known oncogenes and tumor suppressor genes in tumor samples from 133 relapsed myeloma patients participating in phase 2 or 3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.